Propyl-[1,4]dioxan | 823-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: Propyl-[1,4]dioxan
• 英文别名: Propyl-<1,4>dioxan；2-Propyl-1,4-dioxan；Propyldioxan；propyl-[1,4]dioxane；Propyldioxane；2-propyl-1,4-dioxane
• CAS: 823-81-4
• 化学式: C₇H₁₄O₂
• 分子量: 130.187
• InChiKey: BKFVVZSAJWYCGH-UHFFFAOYSA-N

物化性质

• 沸点：
  155.6-157.1 °C(Press: 746 Torr)
• 密度：
  0.943 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  丙基溴化镁 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醚 作用下， 生成 Propyl-[1,4]dioxan
  参考文献：
  名称：

  Monoalkyldioxanes

  摘要：

  DOI：

  10.1021/ja01266a009

文献信息

• CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170360759A1

  公开（公告）日：2017-12-21

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体、药用盐、溶剂化物或前药，其中所有变量均如本文所述。这些化合物是选择性的LPA受体抑制剂。
• N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US10829488B2

  公开（公告）日：2020-11-10

  The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

  本公开提供了具有式 I-A 的化合物：及其药学上可接受的盐和溶液，其中 A、X1、X2、X3 R1a、R1b E 和 = 如说明书中所定义。本公开还提供了式 I-A 的化合物，用于治疗对 Bcl-2 蛋白抑制有反应的疾病、失调或状况，如癌症。
• Tri-cycle compound and applications thereof
  申请人：FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.

  公开号：US11053260B2

  公开（公告）日：2021-07-06

  Disclosed in the present invention are a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt, and applications thereof in the preparation of drugs for treating HBV-related diseases.

  本发明公开了一种由式（I）代表的化合物、其同系物或药学上可接受的盐，以及其在制备治疗 HBV 相关疾病药物中的应用。
• COMPOSITION AND POLYMER
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP2735581B1

  公开（公告）日：2021-07-14
• Composition and Polymer
  申请人：Nakamura Akitake

  公开号：US20140121293A1

  公开（公告）日：2014-05-01

  Disclosed is a composition comprising (A) at least one compound selected from the group consisting of an ether compound having two or more ether groups, a trivalent phosphorus compound, and a ketone compound, (B) a boron trihalide, and (C) an episulfide compound.